June 2016

Michael Fabrizio, MD, and Dana Adams, COO, provide their perspective on the challenges that urology practices face today.

Over the past few months, an alarming number of events have surfaced that we, as providers of oncologic urology care, should take notice.

During the annual American Urological Association meeting leaders in urology presented groundbreaking research, new clinical guidelines, and the latest advances in urologic medicine.

Although androgen deprivation therapy has a survival benefit for patients with high-risk and locally advanced prostate cancer, it is associated with substantial safety concerns, and mixed data exist regarding whether it causes clinically significant depression.

Results from a study using the Decipher Prostate Cancer Classifier noted that its use added very strong data about the likelihood of patients with prostate cancer dying within 10 years.